Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 817: Nivolumab + Ipilimumab in Advanced NSCLC
NCT02869789Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 4 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Oct 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02869789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869789.